UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000043084
Receipt No. R000049188
Scientific Title A verification study of safety evaluation of excessive ingestion of NMN-containing food in humans: a randomized, double-blind, placebo-controlled, parallel study
Date of disclosure of the study information 2021/01/27
Last modified on 2021/06/02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A verification study of safety evaluation of excessive ingestion of NMN-containing food in humans: a randomized, double-blind, placebo-controlled, parallel study
Acronym Safety evaluation of excess ingestion of NMN-containing food in humans.
Scientific Title A verification study of safety evaluation of excessive ingestion of NMN-containing food in humans: a randomized, double-blind, placebo-controlled, parallel study
Scientific Title:Acronym Safety evaluation of excess ingestion of NMN-containing food in humans.
Region
Japan

Condition
Condition Healthy adult
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Safety evaluation of more than five times ingestion of the recommended daily intake of the test food.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes 1. Physical examination
2. Urinalysis
3. Blood test
* Assess these tests at screening (before consumption) and at 2 and 4 weeks after consumption and 2 weeks after consumption completed.
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Intake of NMN-containing food once a day for 4 weeks.
Interventions/Control_2 Intake of placebo without NMN once a day for 4 weeks.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
65 years-old >=
Gender Male and Female
Key inclusion criteria 1)Males and females, aged 20 - 65 years old.
2)Subjects who are deagnosed as eligible to participate in the study by the physician
Key exclusion criteria 1)A medical history of malignant tumor, heart failure or myocardial infarction.
2) Currently undergoing treatment for any of the following chronic diseases: atrial fibrillation, cardiac arrhythmia, liver failure, kidney failure, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
3) Subjects who currently taking medications (including herbal medicines)
4) Subjects who are allergic to medications and/or the test food related products.
5) Subjects who are pregnant, breast-feeding, or planning to become pregnant.
6) Subjects who are judged as ineligible to participate in the study by the physician.
Target sample size 32

Research contact person
Name of lead principal investigator
1st name Atsushi
Middle name
Last name Yamatsu
Organization Pharma Foods International Co., Ltd.
Division name Research and Development Department 1
Zip code 615-8245
Address 1-49 Goryo-Ohara, Nishikyo-ku, Kyoto
TEL 075-748-9829
Email a-yamatsu@pharmafoods.co.jp

Public contact
Name of contact person
1st name Akiko
Middle name
Last name Ishida
Organization Pharma Foods International Co., Ltd.
Division name Research and Development Department 2
Zip code 615-8245
Address 1-49 Goryo-Ohara, Nishikyo-ku, Kyoto
TEL 075-748-9829
Homepage URL
Email a-ishida@pharmafoods.co.jp

Sponsor
Institute Pharma Foods International Co., Ltd.
Institute
Department

Funding Source
Organization Mitsubishi Corporation Life Sciences Limited
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization the ethics committees of Yoga Allergy Clinic
Address 4-32-16, Yoga, Setagaya-ku, Tokyo, Japan
Tel 03-5491-4478
Email jim@medipharma.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2021 Year 01 Month 27 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2020 Year 12 Month 18 Day
Date of IRB
2021 Year 01 Month 15 Day
Anticipated trial start date
2021 Year 01 Month 27 Day
Last follow-up date
2021 Year 03 Month 17 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2021 Year 01 Month 21 Day
Last modified on
2021 Year 06 Month 02 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049188

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.